Herpesvirus hominis Infection in Newborn Mice: Comparison of the Therapeutic Efficacy of 1-β-d-Arabinofuranosylcytosine and 9-β-d-Arabinofuranosyladenine

Intranasal inoculation of newborn mice with Herpesvirus hominis type 2 provides an experimental infection that closely resembles disseminated herpesvirus infection of human newborn infants. After inoculation of mice, the virus multiplies in the respiratory tract and is disseminated through the blood to the liver and spleen and to the brain by both a viremia and nerve route transmission. Although therapy with 1-β-d-arabinofuranosylcytosine (ara-C) did not reduce final mortality, it did increase the mean survival time by 1 day. This effect on the mean survival time was associated with a 1-day delay in the appearance of herpesvirus in the blood, liver, and spleen and a reduction of virus replication in lung and brain for 1 day as compared with untreated control animals. Treatment with 9-β-d-arabinofuranosyladenine (ara-A) likewise had no effect on final mortality, but increased the mean survival time by 2 days. Therapy with ara-A delayed or suppressed virus replication in blood, lung, liver, spleen, and brain for 2 days. Although treatment with either ara-C or ara-A in this experimental H. hominis type 2 infection resulted in a temporary delay and/or suppression of viral replication in several target organs, neither compound was completely effective in inhibiting viral replication or in protecting animals from eventual death due to the infection.

[1]  G. Plummer,et al.  Iododeoxyuridine and Herpesviral Encephalitis: Lack of Inhibitory Action Against Low-Grade Viral Replication , 1974, Antimicrobial Agents and Chemotherapy.

[2]  A. Friedman-kien,et al.  Herpes Simplex Virus Skin Infection in Hairless Mice: Treatment with Antiviral Compounds , 1974, Antimicrobial Agents and Chemotherapy.

[3]  R. Buchanan,et al.  Effect of adenine arabinoside on severe Herpesvirus hominis infections in man. , 1973, The Journal of infectious diseases.

[4]  H. Renis,et al.  Antiviral Activity of Cytarabine in Herpesvirus–Infected Rats , 1973, Antimicrobial Agents and Chemotherapy.

[5]  E. Kern,et al.  Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. , 1973, The Journal of infectious diseases.

[6]  H. Panitch,et al.  Experimental herpes simplex encephalitis. Treatment with pyrimidine nucleosides. , 1973, Archives of neurology.

[7]  M. Lieberman,et al.  Chemotherapy of cutaneous herpesvirus infection of hairless mice. , 1973, The Journal of investigative dermatology.

[8]  A. Chow,et al.  Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients , 1973, Antimicrobial Agents and Chemotherapy.

[9]  I. McLean,et al.  Treatment of Herpes Simplex Virus Types 1 and 2 Encephalitis in Mice with 9-β-d-Arabinofuranosyladenine , 1973, Antimicrobial Agents and Chemotherapy.

[10]  B. Roizman,et al.  Infection with herpes-simplex viruses 1 and 2. 1. , 1973, The New England journal of medicine.

[11]  R. Sidwell,et al.  Target-Organ Treatment of Neurotropic Virus Diseases: Efficacy as a Chemotherapy Tool and Comparison of Activity of Adenine Arabinoside, Cytosine Arabinoside, Idoxuridine, and Trifluorothymidine , 1972, Antimicrobial Agents and Chemotherapy.

[12]  A. Chow,et al.  Susceptibility of Herpesviruses to Cytosine Arabinoside: Standardization of Susceptibility Test Procedure and Relative Resistance of Herpes Simplex Type 2 Strains , 1972, Antimicrobial Agents and Chemotherapy.

[13]  W. Hryniuk,et al.  Cytarabine for herpesvirus infections. , 1972, JAMA.

[14]  P. Sheridan,et al.  Sensitivity of Types 1 and 2 Herpes Simplex Virus to 5-Iodo-2′-Deoxyuridine and 9-β-d-Arabinofuranosyladenine , 1970, Infection and immunity.

[15]  J. Overall,et al.  Virus infections of the fetus and newborn infant. , 1970, The Journal of pediatrics.

[16]  M. Hirsch,et al.  Macrophages and age-dependent resistance to Herpes simplex virus in mice. , 1970, Journal of immunology.

[17]  B. Waisbren,et al.  In vitro determinations of viral susceptibility to drugs for possible clinical use. , 1970, Antimicrobial Agents and Chemotherapy.

[18]  S. Korones,et al.  Infection of the newborn with herpesvirus hominis. , 1970, Advances in pediatrics.

[19]  W. R. Bruce,et al.  Studies on the persistence of methotrexate, cytosine arabinoside, and leucovorin in serum of mice. , 1969, Journal of the National Cancer Institute.

[20]  I. McLean,et al.  Antiviral activity of 0-beta-D-arabinofuranosyladenine. IV. Activity against intracerebral herpes simplex virus infections in mice. , 1968, Antimicrobial agents and chemotherapy.

[21]  G. J. Dixon,et al.  Antiviral activity of 9-beta-D-arabinofuranosyladenine. I. Cell culture studies. , 1968, Antimicrobial agents and chemotherapy.

[22]  J. Schardein,et al.  Antiviral activity of 9-beta-D-arabinofuranosyladenine. 3. Reduction in evidence of encephalitis in treated herpes Simplex-infected hamsters. , 1968, Antimicrobial Agents and Chemotherapy.

[23]  G. J. Dixon,et al.  Antiviral activity of 9-beta-D-arabinofuranosyladenine. II. Activity against Herpes simplex keratitis in hamsters. , 1968, Antimicrobial agents and chemotherapy.

[24]  L. Olson,et al.  Herpesvirus infections of the human central nervous system. , 1967, The New England journal of medicine.

[25]  C. G. Smith,et al.  Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. , 1967, Biochemical pharmacology.

[26]  Richard T. Johnson.  THE PATHOGENESIS OF HERPES VIRUS ENCEPHALITIS. II. A CELLULAR BASIS FOR THE DEVELOPMENT OF RESISTANCE WITH AGE. , 1964 .

[27]  J. Brink,et al.  METABOLISM AND DISTRIBUTION OF 9-BETA-D-ARABINOFURANOSYLADENINE IN MOUSE TISSUES. , 1964, Cancer research.

[28]  D. Buthala,et al.  Cell Culture Studies on Antiviral Agents , 1964, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[29]  E. D. Maloney,et al.  IDU and cytosine arabinoside in experimental herpetic keratitis. , 1963, Archives of ophthalmology.